Animal Parasitic Diseases Laboratory, Animal and Natural Resources Institute, Agricultural Research Service, U.S. Department of Agriculture, Beltsville, MD 20705, USA.
Exp Parasitol. 2011 Sep;129(1):36-41. doi: 10.1016/j.exppara.2011.05.021. Epub 2011 May 24.
The present study was conducted to compare aqueous nanoparticle-based Montanide™ IMS 1313 N VG PR (IMS 1313) and oil-based ISA 71 VG (ISA71) adjuvants in combination with an Eimeria subunit protein vaccine on protection against avian coccidiosis. Male broiler chicks were vaccinated twice with an Eimeria recombinant profilin protein alone or in conjunction with IMS 1313 or ISA 71 prior to infection with live, sporulated Eimeria acervulina oocysts. For comparison, chickens were immunized with a commercial live coccidiosis vaccine (Coccivac-B). The following parameters were assessed as measures of protective immunity: body weight gain, fecal oocyst output, profilin-specific intestinal secretary IgA (sIgA) or IgY antibody levels, and percentages of CD4(+), CD8(+), TCR1(+), or TCR2(+) intestinal intraepithelial lymphocytes (IELs). Birds vaccinated with profilin plus ISA 71 had increased body weight gains, equivalent to Coccivac-B vaccination, compared with the profilin-only group. Immunization with profilin plus IMS 1313, or with profilin plus ISA 71, reduced fecal oocysts shedding compared with the profilin-only group. Intestinal sIgA levels were greater in the profilin plus IMS 1313 or ISA 71 groups, and IgY levels were greater in the profilin plus ISA 71 group, compared with profilin alone. Birds vaccinated with profilin plus IMS 1313 or ISA 71 had higher percentages of CD4(+), CD8(+), and TCR1(+), but not TCR2(+), intestinal IELs compared with the profilin-only vaccinated group. Taken together, these results indicate that immunization of chickens with the recombinant profilin subunit vaccine in conjunction with IMS 1313 or ISA 71 adjuvants increases protective immunity against experimental E. acervulina infection.
本研究旨在比较水性纳米颗粒型 Montanide™ IMS 1313 N VG PR（IMS 1313）和油性 ISA 71 VG（ISA71）佐剂与禽球虫病 Eimeria 亚单位蛋白疫苗联合使用的效果。雄性肉鸡在感染活的、孢子化的柔嫩艾美耳球虫卵囊之前，用 Eimeria 重组原肌球蛋白蛋白单独或与 IMS 1313 或 ISA 71 联合进行两次疫苗接种。为了进行比较，鸡用商业活球虫疫苗（Coccivac-B）进行免疫。评估以下参数作为保护性免疫的衡量标准：体重增加、粪便卵囊排出量、原肌球蛋白特异性肠道分泌型 IgA（sIgA）或 IgY 抗体水平以及 CD4(+)、CD8(+)、TCR1(+)或 TCR2(+)肠道上皮内淋巴细胞（IEL）的百分比。与仅用原肌球蛋白免疫的组相比，用原肌球蛋白加 ISA 71 免疫的鸡体重增加更多，与 Coccivac-B 免疫相当。用原肌球蛋白加 IMS 1313 或原肌球蛋白加 ISA 71 免疫可减少粪便卵囊排出量。与仅用原肌球蛋白免疫的组相比，用原肌球蛋白加 IMS 1313 或 ISA 71 免疫的鸡肠道 sIgA 水平更高，而用原肌球蛋白加 ISA 71 免疫的鸡 IgY 水平更高。与仅用原肌球蛋白免疫的组相比，用原肌球蛋白加 IMS 1313 或 ISA 71 免疫的鸡肠道 CD4(+)、CD8(+)和 TCR1(+)的百分比更高，但 TCR2(+)百分比没有更高。总之，这些结果表明，用重组原肌球蛋白亚单位疫苗与 IMS 1313 或 ISA 71 佐剂联合免疫鸡可增强对实验性柔嫩艾美耳球虫感染的保护性免疫。
